文献速递脑血管病

外周动脉疾病患者的卒中风险与抗血小板治疗

Stroke in Patients With Peripheral Artery Disease.
PubMed 文献 · Stroke · 2019-05-16

中位随访30个月,缺血性卒中、出血性卒中和TIA的累积发生率分别为每100患者年0.87、0.11和0.27。替格瑞洛组调整后缺血性卒中和全因卒中发生率低于氯吡格雷组。

要点

  • 外周动脉疾病患者缺血性卒中和TIA发生率较高,需关注脑血管事件风险。
  • 年龄、既往卒中、房颤/房扑、糖尿病、血压等是全因卒中的独立预测因素。
  • 替格瑞洛较氯吡格雷降低调整后缺血性卒中和全因卒中发生率。

核心结论

  • 在有症状的外周动脉疾病患者中,缺血性卒中和TIA随时间频繁发生。
  • 替格瑞洛相比氯吡格雷与调整后缺血性卒中和全因卒中发生率降低相关。

研究设计与样本

  • 中位随访30个月,对卒中/TIA进行裁定并计算发生率,采用多变量竞争风险模型分析预测因素。

主要发现

  • 共发生458例脑血管事件(317例缺血性卒中、39例出血性卒中、102例TIA),涉及424例患者。
  • 缺血性卒中、出血性卒中和TIA的累积发生率分别为每100患者年0.87、0.11和0.27。
  • 年龄、既往卒中、既往房颤/房扑、糖尿病、地理区域、踝臂指数<0.60、既往截肢和收缩压是与全因卒中独立相关的基线因素。
  • 调整基线因素后,替格瑞洛组缺血性卒中和全因卒中发生率仍低于氯吡格雷组。
  • 两组出血性卒中和TIA发生率无显著差异。

关键数值与推荐

  • 缺血性卒中累积发生率每100患者年0.87。
  • 出血性卒中累积发生率每100患者年0.11。
  • TIA累积发生率每100患者年0.27。
  • 踝臂指数<0.60是与全因卒中独立相关的基线因素之一。

临床怎么用

  • 对有症状外周动脉疾病患者应评估卒中风险,关注年龄、既往卒中、房颤、糖尿病、血压和踝臂指数等因素。
  • 替格瑞洛可作为氯吡格雷的替代选择以降低缺血性卒中和全因卒中风险,但需权衡出血风险。

局限性

  • 本分析为EUCLID试验的事后分析。
  • 原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background and Purpose- Predictors of stroke and transient ischemic attack (TIA) in patients with peripheral artery disease (PAD) are poorly understood. The primary aims of this analysis were to (1) determine the incidence of ischemic/hemorrhagic stroke and TIA in patients with symptomatic PAD, (2) identify predictors of stroke in patients with PAD, and (3) compare the rate of stroke in ticagrelor- and clopidogrel-treated patients. Methods- EUCLID (Examining Use of Ticagrelor in Peripheral Artery Disease) randomized 13 885 patients with symptomatic PAD to receive monotherapy with ticagrelor or clopidogrel for the prevention of major adverse cardiovascular events (cardiovascular death, myocardial infarction, or ischemic stroke). Ischemic/hemorrhagic stroke and TIA were adjudicated and measured as incidence rates postrandomization and cumulative incidence (per patient-years). Post hoc multivariable competing risk hazards analyses were performed using baseline characteristics to determine factors associated with all-cause stroke in patients with PAD. Results- A total of 458 cerebrovascular events in 424 patients (317 ischemic strokes, 39 hemorrhagic strokes, and 102 TIAs) occurred over a median follow-up of 30 months, for a cumulative incidence of 0.87, 0.11, and 0.27 per 100 patient-years, respectively. Age, prior stroke, prior atrial fibrillation/flutter, diabetes mellitus, geographic region, ankle-brachial index <0.60, prior amputation, and systolic blood pressure were independent baseline factors associated with the occurrence of all-cause stroke. After adjustment for baseline factors, the rates of ischemic stroke and all-cause stroke remained lower in patients treated with ticagrelor as compared with those receiving clopidogrel. There was no significant difference in the incidence of hemorrhagic stroke or TIA between the 2 treatment groups. Conclusions- In patients with symptomatic PAD, ischemic stroke and TIA occur frequently over time. Comorbidities such as age, prior stroke, prior atrial fibrillation/flutter, diabetes mellitus, higher blood pressure, prior amputation, lower ankle-brachial index, and geographic region were each independently associated with the occurrence of all-cause stroke. Use of ticagrelor, as compared with clopidogrel, was associated with a lower adjusted rate of ischemic and all-cause stroke. Further study is needed to optimize medical management and risk reduction of all-cause stroke in patients with PAD. Clinical Trial Registration- URL: https://www.clinicaltrials.gov . Unique identifier: NCT01732822.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Kolls BJ, Sapp S, Rockhold FW, et al. Stroke in Patients With Peripheral Artery Disease. Stroke. 2019. PMID: 31092165. doi:10.1161/STROKEAHA.118.023534

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。